BUSINESSSCMP CHINA
Cross-border biotech deals grow more complex as US targets China investment links
Cross-border biotech deals between China and the United States are becoming more complex due to increased U.S. efforts to restrict investment and technology transfers, with analysts predicting a modest slowdown. Geopolitical scrutiny is expected to lead to fewer deals, according to ING Research's Diederik Stadig.
Mentioned
Related Signal
Adjacent reporting
- Cross-border biotech deals grow more complex as US targets China investment links
- China’s biotech industry sees global expansion as unstoppable, despite US pressure
- China's biotech boom alarms Western lawmakers, investors
- STAT+: Pharmalittle: We’re reading about U.S. biotech’s China problem, a Regeneron flop, and much more
- The next tech war? Why biotech may become a new US-China battleground
- China’s biotech industry sees global expansion as unstoppable, despite US pressure